$LH

Schechter Adam H sold $1.5M of LH

Schechter Adam H (President & CEO) sold 4,669 shares of LABCORP HOLDINGS INC. (LH) at $320.37 ($1.50M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schechter Adam H
Published Aug 12, 2026, 6:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new operational or financial information.

03

What to watch

The disclosure does not state motives beyond the pre-arranged plan, and the sale size may be routine relative to holdings.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction filing for Labcorp Holdings (LH) by its President and CEO, Adam H. Schechter.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

SEC Form 4 shows LH CEO Schechter sold 4,669 shares in an open-market transaction on 2026-08-11 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 with a stated 10b5-1 pre-arranged plan and no accompanying guidance, deal, or regulatory action.

Market effects

No sector-level signal; insider sale does not imply industry-wide change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as confidence erosion by some traders.

Key entities

  • LH

    Labcorp Holdings Inc., the company whose insider transaction is disclosed.

  • Schechter Adam H

    President and CEO of LH, reporting an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$LHMedAI 8/10

Labcorp to offer FDA-cleared Elecsys pTau-217 Alzheimer's test

Labcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.

$LHMed

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 4.3% to $307.43 after its 2026 Investor Day, where it reaffirmed revenue guidance of $14.71B-$14.83B and EPS growth of 8.5%-11.5%. The market expected a guidance raise, and the lack of upside led to profit-taking. Broader market declines also pressured the stock.